BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, June 11, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 27, 2017
View Archived Issues
AG-348 well tolerated in updated data from phase II DRIVE PK study
Read More
WHSC1 revealed as a promising therapeutic target for ALL
Read More
Characterization of next-generation anti-CD19 half-life extended BiTE antibody
Read More
TP-0903 demonstrates promising in vitro and in vivo activity
Read More
NuCana BioMed patents adenosine derivatives for cancer
Read More
RedHill Biopharma begins phase IIa study of Yeliva in cholangiocarcinoma
Read More
FGFR inhibitors reported in Shanghai Allist Pharmaceutical patent
Read More
Enlibrium describes biguanide derivatives
Read More
Phase II study of anabasum in SLE begins
Read More
Arrowhead Pharmaceuticals seeks approval for phase I/II study of HBV drug
Read More
FDA issues complete response letter for Agile's Twirla
Read More
Mallinckrodt to acquire Sucampo Pharmaceuticals
Read More
FDA grants fast track designation for VAL-083 in recurrent glioblastoma
Read More
FDA updates Tasigna label to include information on stopping therapy in certain CML patients
Read More
Ono submits supplemental application for Opdivo in Japan
Read More
Poxel and Sumitomo Dainippon Pharma initiate phase III program for imeglimin
Read More
Arno Therapeutics sells remaining assets
Read More
Soliris approved in Japan for the treatment of patients with generalized myasthenia gravis
Read More
CG-806 receives orphan drug designation from FDA for treatment of AML
Read More
FDA grants fast track designation to cannabidiol oral solution for Prader-Willi syndrome
Read More
Agios submits NDA for ivosidenib to treat relapsed/refractory AML with an IDH1 mutation
Read More
Portola Pharmaceuticals provides update on BLA for AndexXa
Read More
Summit acquires Discuva and obtains innovative antibiotic discovery and development platform
Read More
